Related Experiment Video
Updated: Dec 6, 2025

A Postoperative Evaluation Guideline for Computer-Assisted Reconstruction of the Mandible
Published on: January 28, 2020
Adjuvant therapies for MRONJ: A systematic review
Dries Govaerts1, Frederik Piccart1, Anna Ockerman2
1OMFS-IMPATH Research Group, Department of Imaging and Pathology, Faculty of Medicine, Catholic University Leuven, Belgium; Department of Oral and Maxillofacial Surgery, University Hospitals Leuven, Leuven, Belgium.
Adjuvant therapies like laser ablation and leukocyte- and platelet-rich fibrin (LPRF) show promise for healing medication-related osteonecrosis of the jaw (MRONJ). However, more research is needed due to the current low evidence base.
Area of Science:
- Oral surgery
- Oncology
- Pharmacology
Background:
- Medication-related osteonecrosis of the jaw (MRONJ) is a severe complication of antiresorptive and antiangiogenic medications.
- Current treatments for MRONJ include conservative medical and surgical approaches, with limited options for stimulating healing.
- Adjuvant therapies are being explored to improve outcomes in MRONJ patients.
Purpose of the Study:
- To systematically review and compare the effectiveness of adjuvant therapies for MRONJ.
- To evaluate the outcomes of laser ablation, leukocyte- and platelet-rich fibrin (LPRF), and fluorescence-guided surgery in MRONJ treatment.
Main Methods:
- A systematic review following PRISMA guidelines was conducted.
- Literature search performed across major databases (PubMed, Embase, Web of Science, Cochrane).
- Thirty articles were included from 3297 initial records, focusing on mucosal healing in MRONJ patients treated with adjuvant therapies.
Main Results:
- Laser ablation demonstrated a 60-95% success rate for complete mucosal healing.
- Leukocyte- and platelet-rich fibrin (LPRF) showed a 60-100% success rate in controlled trials.
- Fluorescence-guided surgery achieved an 85-90% complete healing rate.
Conclusions:
- Laser ablation, LPRF, and fluorescence-guided surgery show potential as adjuvant therapies for MRONJ.
- Most studies reviewed had a medium to high risk of bias, necessitating cautious interpretation.
- Further randomized controlled trials are essential to establish optimal therapeutic protocols and confirm efficacy.
More Related Videos
Related Concept Videos
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Bone Remodeling
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Urinary Tract Calculi III: Medical Management
Osteoclasts in Bone Remodeling

